Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05260021 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 99
- Enrollment target
NCT05260021 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 99 participants.
The verdict
NCT05260021, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both. The overall study will last about 60 weeks with up to 14 clinic visits and 6 phone visits. Clinic visits will include blood sample collection, physical exam and questionnaire.
Interventions
- DRUG Placebo
- DRUG Tirzepatide Dose 1
- DRUG Tirzepatide Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2022-04-13 |
| Est. Completion | 2025-01-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05260021
The ClinicalTrials.gov registry entry for NCT05260021 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05260021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05260021 about?
NCT05260021 is a clinical study titled "A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both". The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both. The overall study will last about 60 weeks with up to 14 clinic visits and 6 phone visits. Clinic vi...
What is the current status of trial NCT05260021?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 99 participants. The study started on 2022-04-13. Estimated completion is 2025-01-28.
What interventions are being tested in trial NCT05260021?
The interventions under investigation include: Placebo (DRUG), Tirzepatide Dose 1 (DRUG), Tirzepatide Dose 2 (DRUG).
Who is sponsoring clinical trial NCT05260021?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.